No votes yet

Chemotherapy-Induced Peripheral Neuropathy

Terri Armstrong
Lois Almadrones
Mark R. Gilbert
ONF 2005, 32(2), 305-311 DOI: 10.1188/05.ONF.305-311

Purpose/Objectives: To review the literature documenting the scope, treatment, and prevention of chemotherapy-induced neuropathy.


Aghajanian, C., Soignet, S., Dizon, D.S., Pien, C.S., Adams, J., Elliott, P.J., et al. (2002). A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. <i>Clinical Cancer Research, 8</i>, 2505-2511.

Almadrones, L., Armstrong, T., Gilbert, M., & Schwartz, R. (2002). <i>Chemotherapy-induced neurotoxicity: Current trends in management. A multidisciplinary approach.</i> Philadelphia: Phillips Group Oncology Communications.

Almadrones, L.A., & Arcot, R. (1999). Patient guide to peripheral neuropathy. <i>Oncology Nursing Forum, 26</i>, 1359-1360.

Aventis Pharmaceuticals. (2003). Taxotere® (docetaxel) injection [Package insert]. Bridgewater, NJ: Author.

Barbano, R., Hart-Gouleau, S., Pennella-Vaughan, J., & Dworkin, R.H. (2003). Pharmacotherapy of painful diabetic neuropathy. <i>Current Pain and Headache Reports, 7</i>, 169-177.

Bristol-Myers Squibb Company. (2000). Taxol® (paclitaxel) injection [Package insert]. New York: Author.

Cassileth, B.R., Vickers, A., Seidler, A., & Miner, W. (2002). Significant reductions in fatigue, pain, nausea, anxiety and depression following massage therapy [Abstract 1471]. <i>Proceedings of the American Society of Clinical Oncology, 21</i>, 368a.

Cavaletti, G., Marzorati, L., Bogliun, G., Colombo, N., Marzola, M., Pittelli, M.R., et al. (1992). Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. <i>Cancer, 69</i>, 203-207.

Cavaletti, G., & Zanna, C. (2002). Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. <i>European Journal of Cancer, 38</i>, 1832-1837.

Cersosimo, R.J. (1989). Cisplatin neurotoxicity. <i>Cancer Treatment Reviews, 16</i>, 195-211.

Dyck, P.J., Dyck, P.J., Grant, I.A., & Fealey, R.D. (1996). Ten steps in characterizing and diagnosing patients with peripheral neuropathy. <i>Neurology, 47</i>, 10-17.

Furlong, T.G. (1993). Neurologic complications of immunosuppressive cancer therapy. <i>Oncology Nursing Forum, 20</i>, 1337-1352.

Gilbert, M.R. (2000). Neurologic complications. In M.D. Abeloff, J.O. Armitage, A.S. Lichter, & J.E. Neiderhuber (Eds.), <i>Clinical oncology</i> (2nd ed., pp. 89-105). New York: Churchill Livingstone.

Haim, N., Barron, S.A., & Robinson, E. (1991). Muscle cramps associated with vincristine therapy. <i>Acta Oncologica, 30</i>, 707-711.

Hay, J.W. (2002). Quality of life effects of chemotherapy-induced neuropathy in ovarian cancer [Abstract 886]. <i>Proceedings of the American Society of Clinical Oncology, 21</i>, 222a.

Hilkens, P.H., Verweij, J., Stoter, G., Vecht, C.J., van Putten, W.L., & van den Bent, M.J. (1996). Peripheral neurotoxicity induced by docetaxel. <i>Neurology, 46</i>, 104-108.

Hohneker, J.A. (1994). A summary of vinorelbine (Navelbine) safety data from North American clinical trials. <i>Seminars in Oncology, 21</i>(Suppl. 10), 42-47.

Holden, S., & Felde, G. (1987). Nursing care of patients experiencing cisplatin-related peripheral neuropathy. <i>Oncology Nursing Forum, 14</i>(1), 13-17.

Holland, J.F., Scharlau, C., Gailani, S., Krant, M.J., Olson, K.B., Horton, J., et al. (1973). Vincristine treatment of advanced cancer: A cooperative study of 392 cases. <i>Cancer Research, 33</i>, 1258-1264.

Jacobson, S.D., Loprinzi, C.L., Sloan, J.A., Wilke, J.L., Novotny, P.J., Okuno, S.H., et al. (2002). Glutamine for preventing paclitaxel-associated myalgias and arthralgias: Unfortunately a "no go" [Abstract 1460]. <i>Proceedings of the American Society of Clinical Oncology, 21</i>, 366a.

Kaplan, E., Kleinman, M., Patel, A., Kozloff, M., Tangonan, C., Cowan, M., et al. (2001). Amifostine as a rescue agent in patients with chemotherapy-induced peripheral neuropathy [Abstract 2959]. <i>Proceedings of the American Society of Clinical Oncology, 20</i>, 302b.

Kaplan, R.S., & Wiernik, P.H. (1982). Neurotoxicity of antineoplastic drugs. <i>Seminars in Oncology, 9</i>, 103-130.

Kemp, G., Rose, P., Lurain, J., Berman, M., Manetta, A., Roullet, B., et al. (1996). Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. <i>Journal of Clinical Oncology, 14</i>, 2101-2112.

Legha, S.S. (1986). Vincristine neurotoxicity. Pathophysiology and management. <i>Medical Toxicology, 1</i>, 421-427.

Lipton, R.B., Apfel, S.C., Dutcher, J.P., Rosenberg, R., Kaplan, J., & Berger, A. (1989). Taxol produces a predominantly sensory neuropathy. <i>Neurology, 39</i>, 368-373.

Lorusso, D., Ferrandina, G., Greggi, S., Gadducci, A., Pignata, S., Tateo, S., et al. (2003). Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. <i>Annals of Oncology, 14</i>, 1086-1093.

Pazdur, R., Kudelka, A.P., Kavanagh, J.J., Cohen, P.R., & Raber, M.N. (1993). The taxoids: Paclitaxel (Taxol) and docetaxel (Taxotere). <i>Cancer Treatment Reviews, 19</i>, 351-386.

Pollera, C.F., Pietrangeli, A., & Giannarelli, D. (1991). Cisplatin-induced peripheral neurotoxicity: Relationship to dose intensity. <i>Annals of Oncology, 2</i>, 212.

Quasthoff, S., & Hartung, H.P. (2002). Chemotherapy-induced peripheral neuropathy. <i>Journal of Neurology, 249</i>, 9-17.

Rambaud, L., Freyer, G., Taieb, S., Guilloton, L., Descos, L., Gaget, R., et al. (2001). Managing oxaliplatin (OXA) neurosensory toxicity: The use of somesthetic evoked potentials (SEP) is no more discriminating than a rigorous clinical follow-up [Abstract 1627]. <i>Proceedings of the American Society of Clinical Oncology, 20</i>, 408a.

Rapoport, B.L., Vorobiof, D.A., Chasen, M.R., McMichael, G., Cohen, G., Eek, R., et al. (2002). Low incidence of neurotoxicity in patients (pts) undergoing chemotherapy with docetaxel and carboplatin (CBDCA): Results of a phase II first line study in advanced ovarian cancer [Abstract 862]. <i>Proceedings of the American Society of Clinical Oncology, 21</i>, 216a.

Richardson, P. (2003). Clinical update: Proteasome inhibitors in hematologic malignancies. <i>Cancer Treatment Reviews, 29</i>(Suppl. 1), 33-39.

Roca, E., Bruera, E., Politi, P.M., Barugel, M., Cedaro, L., Carraro, S., et al. (1985). Vinca alkaloid-induced cardiovascular autonomic neuropathy. <i>Cancer Treatment Reports, 69</i>, 149-151.

Roelofs, R.I., Hrushesky, W., Rogin, J., & Rosenberg, L. (1984). Peripheral sensory neuropathy and cisplatin chemotherapy. <i>Neurology, 34</i>, 934-938.

Rosenthal, S., & Kaufman, S. (1974). Vincristine neurotoxicity. <i>Annals of Internal Medicine, 80</i>, 733-787.

Rowinsky, E.K., Chaudhry, V., Forastiere, A.A., Sartorius, S.E., Ettinger, D.S., Grochow, L.B., et al. (1993). Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting. <i>Journal of Clinical Oncology, 11</i>, 2010-2020.

Rowinsky, E.K., Eisenhauer, E.A., Chaudhry, V., Arbuck, S.G., & Donehower, R.C. (1993). Clinical toxicities encountered with paclitaxel (Taxol). <i>Seminars in Oncology, 20</i>(4, Suppl. 3), 1-15.

Schaible, H., & Richter, F. (2004). Pathophysiology of pain. <i>Current Concepts in Clinical Surgery.</i> Retrieved May 4,2004, from http://springerlink.metapress.com

Teravainen, H., & Larsen, A. (1977). Some features of the neuromuscular complications of pulmonary carcinoma. <i>Annals of Neurology, 2</i>, 495-502.

Thompson, S.W., Davis, L.E., Kornfeld, M., Hilgers, R.D., & Standefer, J.C. (1984). Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. <i>Cancer, 54</i>, 1269-1275.

Vahdat, L., Papadopoulos, K., Lange, D., Leuin, S., Kaufman, E., Donovan, D., et al. (2001). Reduction of paclitaxel-induced peripheral neuropathy with glutamine. <i>Clinical Cancer Research, 7</i>, 1192-1197.

van Gerven, J.M., Moll, J.W., van den Bent, M.J., Bontenbal, M., van der Burg, M.E., Verweij, J., et al. (1994). Paclitaxel (Taxol) induces cumulative mild neurotoxicity. <i>European Journal of Cancer, 30A</i>, 1074-1077.

Vasey, P.A. (2002). Survival and longer-term toxicity results of the SCOTROC study: Docetaxel-carboplatin (DC) vs. paclitaxel-carboplatin (PC) in epithelial ovarian cancer (EOC) [Abstract 804]. <i>Proceedings of the American Society of Clinical Oncology, 21</i>, 202a.

von Schlippe, M., Fowler, C.J., & Harland, S.J. (2001). Cisplatin neurotoxicity in the treatment of testicular germ cell tumour: Incidence, time course and prognosis [Abstract 776]. <i>Proceedings of the American Society of Clinical Oncology, 20</i>, 195a.

Walsh, T.J., Clark, A.W., Parhad, I.M., & Green, W.R. (1982). Neurotoxic effects of cisplatin therapy. <i>Archives of Neurology, 39</i>, 719-720.

Yalcin, S., Nurlu, G., Orhan, B., Zeybek, D., Muftuoglu, S., Sarer, B., et al. (2003). Protective effect of amifostine against cisplatin-induced motor neuropathy in rat. <i>Medical Oncology, 20</i>, 175-180.